Malignant gliomas
- 1 May 2004
- journal article
- review article
- Published by Springer Nature in Current Neurology and Neuroscience Reports
- Vol. 4 (3) , 218-227
- https://doi.org/10.1007/s11910-004-0042-4
Abstract
Malignant gliomas are the most common type of primary brain tumor. Although therapy for patients with these tumors remains limited, there has been important progress recently. In this review, some of these advances are discussed, with an emphasis on targeted molecular therapies.Keywords
This publication has 96 references indexed in Scilit:
- Phase 1 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: A North American Brain Tumor Consortium studyNeuro-Oncology, 2004
- Phase 2 study of weekly irinotecan in adults with recurrent malignant glioma: Final report of NABTT 97-11Neuro-Oncology, 2004
- Phase II Trial of Thalidomide and Carmustine for Patients With Recurrent High-Grade GliomasJournal of Clinical Oncology, 2003
- Two studies evaluating irinotecan treatment for recurrent malignant glioma using an every-3-week regimenCancer, 2003
- Recent developments in the molecular characterization and treatment of oligodendroglial tumorsNeuro-Oncology, 2003
- Distribution of STI-571 to the Brain Is Limited by P-Glycoprotein-Mediated EffluxThe Journal of Pharmacology and Experimental Therapeutics, 2003
- Combination of epidermal growth factor receptor targeted therapy with radiation therapy for malignant gliomasFrontiers in Bioscience-Landmark, 2003
- Phase II Trial of Murine 131I-Labeled Antitenascin Monoclonal Antibody 81C6 Administered Into Surgically Created Resection Cavities of Patients With Newly Diagnosed Malignant GliomasJournal of Clinical Oncology, 2002
- A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapseBritish Journal of Cancer, 2000
- Expression of PDGF and PDGF receptors in human astrocytoma operation specimens supports the existence of an autocrine loopInternational Journal of Cancer, 1995